#China #Nanjing #Roche #Simcere Zaiming #SIM0660

Simcere Zaiming Collaborates with Roche for Groundbreaking Therapeutics

In a significant advancement for cancer treatment, Simcere Zaiming, a subsidiary of the Simcere Pharmaceutical Group (2096.HK), has announced an exclusive global license agreement with Roche for the development and commercialization of SIM0660. This innovative trispecific antibody is designed to target key molecules CD79a, CD19, and CD3, showing great promise in addressing B-cell mediated diseases.

According to the agreement, Roche will acquire exclusive global rights for the development, manufacturing, and commercialization of SIM0660. Simcere Zaiming stands to gain up to $1.53 billion from this collaboration, with $75 million immediately payable upfront and potential tiered royalties based on future net sales.

Understanding SIM0660
SIM0660 represents a cutting-edge therapeutic option, built on advanced poly-specific antibody technology developed by Simcere Zaiming. The antibody employs a unique approach by combining a CD3 engagement arm with binding domains targeting both CD79a and CD19 antigens on B-cells. This dual-target strategy aims to unleash powerful T-cell mediated cytotoxicity while minimizing cytokine release, which is often associated with adverse side effects.

As one of the first trispecific antibodies in its category, SIM0660 promises extensive coverage for diseases mediated by B-cells, offering a differentiated therapeutic alternative for patients who have previously been treated with therapies targeting CD20 and CD19. Furthermore, SIM0660 holds potential therapeutic benefits for autoimmune conditions involving B-cell mediation, where the targeted destruction of pathogenic B-cells could lead to significant clinical improvements.

Voices of Collaboration
Renhong Tang, the CEO of Simcere Zaiming, expressed enthusiasm for the new partnership, stating, "We are committed to developing highly innovative T-cell engagers through our exclusive TCE platform. Partnering with Roche will allow us to accelerate the clinical development of SIM0660. We anticipate that our synergistic innovation will soon provide much-needed solutions for patients worldwide."

Boris L. Zaïtra, Roche's head of business development, echoed the significance of this collaboration, noting, "This agreement with Simcere Zaiming highlights our commitment to partnering with innovative companies to create and deliver new treatment options for patients in need. The SIM0660 has the potential to be a major breakthrough for those suffering from B-cell mediated diseases."

To date, Simcere Pharmaceutical Group has concluded six licensing transactions that could yield over $6.1 billion in potential revenue. This continued collaboration demonstrates the growing interest and investment in innovative therapeutic solutions.

About Simcere Zaiming
Simcere Zaiming is a biotech firm focused on oncology and a key subsidiary of Simcere Pharmaceutical Group Limited (2096.HK). The company dedicates itself to developing innovative therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative research and development portfolio that includes unique clinical assets, Simcere Zaiming has successfully launched several groundbreaking products in China, such as Enzeshu, COSELA, and others. The firm aims to provide transformative therapeutic options for cancer patients worldwide through its in-house R&D, manufacturing, and marketing capabilities, complemented by strategic collaborations with leading partners.